Recently, a STING‐PROTAC synthesized using a STING antagonist as the STING binding warhead has been successfully developed,[68] and it will be interesting to test if treating RCC with this STING‐PROTAC reduces RCC proliferation through increasing mitochondrial ROS/calcium homeostasis. Here, STING1 is linked to renal cell carcinoma.